Brief: Gensight Biologics End-March Cash At 36 Million Euros

Gensight Biologics SA

21/04/2022 06:35

April 21 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS REPORTS CASH POSITION AND REVENUES AS
OF
MARCH 31, 2022
    * EUR 36.0 MILLION OF CASH AS OF MARCH 31, 2022; RUNWAY
CONFIRMED
TO EARLY Q1 2023
    * WITH A CURRENT CASH RUNWAY TO EARLY Q1 2023, WE ARE
ASSESSING
SEVERAL FINANCING OPTIONS, NON OR AS LITTLE DILUTIVE AS
POSSIBLE, TO ENSURE A SUCCESSFUL EUROPEAN COMMERCIAL LAUNCH OF
LUMEVOQ IN 2023 - CFO

Source text for Eikon:  ID:nBw8MFG75a 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))